|Bid||56.80 x 800|
|Ask||0.00 x 1000|
|Day's Range||71.36 - 73.98|
|52 Week Range||50.87 - 85.07|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||91.40|
|Earnings Date||Dec 02, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.92|
The major stock indexes were higher ahead of the signing of the phase-one China trade deal. Target dove 7% on weak holiday sales.
DRAPER, Utah, Jan. 15, 2020 -- HealthEquity (NASDAQ: HQY), a leading provider of health savings accounts (HSAs) and complementary consumer-directed benefits (CDBs), announced.
HealthEquity also announced it will provide final sales results for its fiscal year 2020, on February 18, 2020, while providing estimates of HSA members, HSA assets and Total Accounts for its fiscal year ending on January 31, 2020.
Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
HealthEquity shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.